COLL
Collegium PharmaceuticalBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Q1 showed solid top-line growth, JORNAY PM momentum, durable pain-portfolio revenue, strong cash generation, and an accretive AZSTARYS acquisition that should deepen the ADHD franchise and extend the revenue base.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
AZSTARYS integration and ramp could underdeliver, especially with about $300M of delayed-draw term-loan funding and up to $135M of contingent milestones [#IR-2026-05-12].
Momentum
17
Value
72
Sentiment
87
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $42.00 · Bull $58.00 · Bear $26.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $53.83
Why
Momentum17 · Δ7d +0.9
Value72 · Δ7d +0.3
Sentiment87 · Δ7d +6.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
17
34% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
-7.1
Value
72
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.5
Sentiment
87
33% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+18.5
Why this grade
Composite grade B. Momentum 16.6 / Value 71.7 / Sentiment 87.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.03B
Beta
0.65
Shares Out
31.61M
P/E (TTM)
28.5
P/S (TTM)
1.91
P/FCF (TTM)
4.99
Rev YoY
+31.4%
EPS YoY
+213.2%
Gross Margin
+57.2%
Op Margin
+20.7%
Net Debt
$689.73M
Current Ratio
1.36
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology